Table 5

HR, with 95% CI and p values, for the effect of RA, AS, PSA, SLE and SSc on all-cause mortality of patients <50 years and ≥50 years of age for the first 3 years (0–36 months) and for the following 2 years (>36 months) of follow-up

Systemic rheumatic diseaseAge (years)0–36 months of follow-up>36 months of follow-up
HR (main effect)HR (main effect)
95% CIP value95% CIP value
RA<500.430.28 to 0.69<0.0011.36**0.72 to 2.590.345
≥500.630.60 to 0.67<0.0011.12*1.04 to 1.210.002
AS<500.570.33 to 0.960.0370.570.33 to 0.960.037
≥500.650.52 to 0.83<0.0011.04**0.77 to 1.410.806
PsA<500.520.28 to 0.950.0360.520.28 to 0.950.036
≥500.690.60 to 0.79<0.0011.08*0.89 to 1.310.418
SLE<502.741.92 to 3.92<0.0012.741.92 to 3.92<0.001
≥501.471.30 to 1.66<0.0011.89*1.59 to 2.25<0.001
SSc<505.182.71 to 9.89<0.0015.182.71 to 9.89<0.001
≥502.21.82 to 2.66<0.0014.01**3.00 to 5.37<0.001
  • P value for interaction *<0.001; **<0.05.

  • AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.